Skip to main content
. 2018 Mar 21;19(6):454–460. doi: 10.1080/15384047.2018.1433498

Figure 2.

Figure 2.

Progression-Free Survival (PFS) in relation to EGFR staining on CTCs from sarcoma patients. A) PFS of all patients included. EGFR expression in STS patients (> 83% = positive EGFR staining on CTCs 2.2 months); ≤ 83% = negative EGFR staining on CTCs (NR) (p = 0.117). B) PFS including only patients treated in first line. EGFR + CTCs was 2.2 months versus NR, for EGFR- CTCs (p = 0.156). Notes: Dotted line: patients without expression of EGFR. Continuous line: patients with expression of EGFR. NR = not reached.